SCIENTURE HOLDINGS INC (SCNX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$0.37+0.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · SCNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 289.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 4 industry peers · Company calendar date is not available
SCNX — CEO transition
Dated 2026-05-29
CFO — Eric Sherb: Eric Sherb resigned as CFO due to personal reasons.
Why it matters: A successful launch will prove the company's plan and grow its product line.
Supportive ifThere will be an official launch date for REZENOPY™. Initial orders will be fulfilled.
Worry ifDelay in the launch of REZENOPY™ beyond Q3 2026.
Why it matters: Managing expenses well is important. It helps improve profits and financial health.
Supportive ifIn Q3 2026, operating costs fall below $2.5 million.
Worry ifIn Q3 2026, operating costs remain above $3.0 million.
Why it matters: Increased payer access will drive sales growth and market penetration for Arbli™.
Supportive ifAnnouncement of new payer agreements for an extra 5 million lives for Arbli™.
Worry ifNo new payer agreements announced in the next quarter.
Why it matters: If revenue keeps growing, it shows the strategy is working. This is important for making money in the future.
Supportive ifQ2 2026 revenue from Arbli TM exceeds $100 thousand, indicating strong demand.
Worry ifQ2 2026 revenue from Arbli TM is below $50 thousand, suggesting weak market traction.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$225 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $890 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,073 loss on $10,000 · 90.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A stronger cash position helps with growth plans and stability.
Supportive ifCash and equivalents increase to over $12 million by Q4 2026.
Worry ifCash and equivalents fall below $10 million by Q4 2026.
Why it matters: New patents can help keep the market exclusive. They can also boost sales for Arbli™ and REZENOPY™.
Supportive ifSales of Arbli™ and REZENOPY™ go up by at least 30% after patent news.
Worry ifSales remain flat or decline despite new patent protections.
Why it matters: Successful product launches are key to revenue growth and market presence. Delays or failures could hurt investor confidence.
Supportive ifLook for news about successful sales or good numbers for Arbli TM and REZENOPY TM.
Worry ifWatch for no updates or bad news about Arbli TM and REZENOPY TM.
Why it matters: More prescriptions show that Arbli TM is being accepted in the market.
Supportive ifMonthly prescription growth keeps rising. This shows market acceptance.
Worry ifPrescription growth stops or goes down. This means there are market problems.
Why it matters: How the company manages its debt affects its financial health and stability. This is crucial for investor trust.
Watch forLook for good news on paying back or changing the $8.42 million in notes.
Also watch forWatch for bad news about not meeting payments or more debt.
Why it matters: More agreements will help reach more markets. This can increase sales for REZENOPY TM.
Supportive ifThere are new GPO agreements for over 1,000 healthcare institutions.
Worry ifNo new GPO agreements announced within the next quarter.
Why it matters: Earnings results will show how well revenue is growing and how expenses are managed.
Watch forEarnings show revenue growth above $400,000 and reduced net loss.
Also watch forEarnings report shows revenue below $300,000 and increased net loss.
Why it matters: Lower costs will help the company make money. This keeps the company strong.
Supportive ifIn Q3 2026, costs drop below $2.5 million.
Worry ifIn Q3 2026, costs rise above $3.0 million.
Why it matters: Strong revenue growth from REZENOPY™ would show successful market entry and demand for the product.
Supportive ifQ3 2026 revenue from REZENOPY™ exceeds $100,000.
Worry ifQ3 2026 revenue from REZENOPY™ is below $50,000.
Why it matters: New patents help strengthen market position and keep products exclusive.
Supportive ifNew patents for REZENOPY or ARBLI have been granted.
Worry ifNo new patents granted for either product by the end of 2026.